Questions? Chat with the founder on WhatsApp

Chat with the founder on WhatsApp
Arthneeti
HomeRankingsIPOScreenerInstitutions
HomeRankingsIPOScreenerInstitutions
Acutaas Chemicals LtdQ1 FY27Pharmaceuticals & Biotechnology
Home/Stocks/Acutaas Chemicals Ltd/Q1 FY27

Acutaas Chemicals Ltd Q1 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹3,311P/E: 67.2Market Cap: ₹25.9K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

N/A

Margin

N/A

Fundraise

N/A

Order

N/A

Capex

N/A

0 of 0 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

No information is provided regarding the same in the latest conference call.

Margin guidance

No information is provided regarding the same in the latest conference call.

3 more insights locked — sign up free to unlock

Fundraise plans

No information is provided regarding the same in the latest conference call.

Order book

No information is provided regarding the same in the latest conference call.

Capex plans

No information is provided regarding the same in the latest conference call.

How does Acutaas Chemicals Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
1Acutaas Chemicals Ltd
2Pharmaceuticals & Biotechnology Company A
Rev 1Mar 2
3Pharmaceuticals & Biotechnology Company B
Rev 2Mar 1
4Pharmaceuticals & Biotechnology Company C
Rev 2Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

How does Acutaas Chemicals Ltd rank in Pharmaceuticals & Biotechnology?

Compare Acutaas Chemicals Ltd against every Pharmaceuticals & Biotechnology company (Q1 FY27) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Related research

Other quarters — Acutaas Chemicals Ltd

Q4 FY26Q3 FY26Q2 FY26Q1 FY26Q4 FY25Q3 FY25Q2 FY25Q1 FY25Q4 FY24Q3 FY24Q2 FY24Q1 FY24

Pharmaceuticals & Biotechnology peers

Abbott India Ltd · Q1 FY23Aurobindo Pharma · Q1 FY27Biocon · Q1 FY27Zydus Lifesciences Ltd · Q1 FY27Cipla · Q1 FY27
Acutaas Chemicals Ltd full stock analysisPharmaceuticals & Biotechnology sectorEarnings call directoryRankings dashboard

Questions about this analysis? Chat directly with the founder — real answers about the research, not a support bot.

WhatsApp the founder

Research team or advisory firm? Get earnings-call intelligence and ranking history as research inputs for your firm.

For Institutions

Arthneeti AI

AI-powered stock analysis from earnings call transcripts. Helping Indian investors make smarter decisions with data-driven insights.

Analysis

  • Stock Rankings
  • Sectors
  • Compare Stocks
  • IPO Dashboard
  • Stock Screener
  • Earnings Call Analysis
  • Stocks Under ₹500
  • Multibaggers

Tools

  • MF Overlap Checker
  • SIP Calculator
  • CAGR Calculator
  • FD vs Equity
  • All Calculators

Resources

  • Blog
  • Weekly Digest
  • Portfolio Analysis
  • Build Portfolio
  • Earnings Calendar
  • Q1 FY27 Earnings Hub

Company

  • Pricing
  • How Our Analysis Works
  • For Institutions
  • Terms of Service
  • Privacy Policy

Compare

  • vs Screener.in
  • vs Trendlyne
  • vs Tickertape
  • vs Moneycontrol Pro
+91 90841 32575 support@arthneeti.com Bengaluru, India

© 2026 Arthneeti AI. All rights reserved.

AI-analyzed data from 1,500+ company earnings calls

Continue your research

What Acutaas Chemicals Ltd's management said in earlier quarters

  • Q4 FY26 earnings call analysis →
  • Q3 FY26 earnings call analysis →
  • Q2 FY26 earnings call analysis →

Others in Pharmaceuticals & Biotechnology this season

  • Senores Pharma. (Q1 FY27)

    Capex planned at **INR 100-120 crores** in FY27 mainly for capacity expansion. Key concall takeaways from Senores Pharma.'s Q1 FY27 earnings call — and how it…

  • Jagsonpal Pharmaceuticals Ltd (Q1 FY27)

    Overall operating EBITDA grew 21% YoY in Q1 FY27; PAT increased 22%, with margin expansions of 240 bps and 176 bps respectively. Key concall takeaways from…

  • Indoco Remedies (Q1 FY27)

    As of Q1 FY27, Indoco Remedies Limited has an order book exceeding INR 250 crores for execution. Key concall takeaways from Indoco Remedies's Q1 FY27 earnings…

  • Mankind Pharma (Q1 FY27)

    Acute segment has shown steady recovery, reaching growth comparable to Indian Pharmaceutical Market (IPM) at 10.9%. Key concall takeaways from Mankind Pharma's…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharma.